BNB Plus completes record LineaDNA order as strategic review puts LineaRx in sharper focus
BNB Plus completed a record $1.2 million LineaDNA order for LineaRx. Read what it means for scale, margins, strategy, and BNBX stock sentiment.
Medical Devices & Diagnostics
Pharma & Biotech
Could Entos Pharmaceuticals’ Fusogenix platform open a real path to treatment in L-CMD?
Entos Pharmaceuticals and the L-CMD Research Foundation are targeting a curative L-CMD therapy. Read what this could change for rare disease treatment.
Pharma & Biotech
Scribe Therapeutics deepens in vivo CRISPR validation with second Eli Lilly collaboration milestone
Scribe Therapeutics hits a second in vivo CRISPR milestone with Eli Lilly. Explore what this changes for gene editing platforms and future therapies.
Pharma & Biotech
What Lilly’s Orna Therapeutics deal means for immune reset strategies
Eli Lilly and Company has entered into a definitive agreement to acquire Orna Therapeutics, Inc., gaining access to the biotechnology firm’s circular RNA platform and its clinical trial ready in vivo CAR-T candidate ORN-252 targeting CD19 for B cell driven autoimmune diseases. The deal, valued at up to 2.4 billion dollars in cash including milestone